+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Young Investigator Award in Biomedicines

Biomedicines

The Biomedicines Young Investigator Award was established in 2020 to acknowledge the achievements of young investigators in the field of biomedicines. Nominations will be accepted from May through December each year, with winners notified by the end of March the following year.

The Prize:
– CHF 1000;
– An Electronic Certificate
– A free voucher for article processing fees valid for one year.

Number of Winners: 2

List of Documents for Application

– Detailed curriculum vitae, including an updated publication list and a list of the researcher’s own research grants;
– Scanned copy of doctorate certificate;
– Signed nomination letters from two established senior scientists.

AI Based Application Success Predictor

✅ 1. Strong translational framing

This is the single strongest predictor.

Successful manuscripts:

explicitly describe clinical relevance,

outline diagnostic/therapeutic implications,

map bench findings to bedside outcomes.

Purely descriptive biomolecular work does less well.

✅ 2. Disease-focused narrative

Highly cited Biomedicines papers:

focus on a specific disease context,

compare to clinical standards of care,

discuss unmet patient needs.

Vague “biological process” framing underperforms.

✅ 3. Inclusion of high-value biomarkers

Patterns in accepted manuscripts:

circulating biomarkers (NfL, microRNAs, cytokines, ctDNA),

imaging correlations,

prognostic stratifiers.

Biomarkers create a clear translational hook.

✅ 4. Multi-omics or multi-modal data

Consistently favored combinations:

Transcriptomics + protein validation,

Genomics + functional assays,

Imaging + molecular profiling.

Single-layer datasets are accepted, but multi-layer improves reviewer enthusiasm.

✅ 5. Mechanistic clarity

Even for clinical papers, reviewers reward mechanism hypotheses:

pathway activation logic,

upstream regulatory rationale,

downstream functional consequences.

Weak mechanism = “interesting but incomplete.”

✅ 6. Therapeutic angle

Articles that:

repurpose drugs,

test targeted inhibitors,

use immunomodulators,

evaluate delivery platforms

receive more editorial interest.

✅ 7. Modern methodology signals (editorial preference)

Winning patterns:

machine learning for prediction,

single-cell profiling,

immune landscape mapping,

3D organoids.

These keywords correlate with higher acceptance probability.

✅ 8. Adequate sample size / statistics

Common pitfalls:

small n without power justification,

missing effect sizes,

lack of adjustment for multiple testing.

Simple power reasoning can save a manuscript.

✅ 9. Clearly described methodology

MDPI reviewers repeatedly request:

reagent details,

instrumentation parameters,

data acquisition pipelines.

Opaque methods trigger major revisions.

✅ 10. Comparative literature positioning

Successful submissions:

map improvements over current diagnostics/therapeutics,

use structured comparisons,

avoid generic “more research is needed.”

Contrast sells.

✅ 11. Ethical/IRB compliance clarity

Biomedicines reviewers scrutinize:

patient consent,

tissue approvals,

animal care protocols.

Ambiguity invites re-review delays.

✅ 12. Clean, well-annotated visuals

Patterns:

well-labeled figures with readable fonts,

quantification accompanying microscopy,

statistical overlays on plots.

Messy visuals → instant reviewer complaints.

✅ 13. Robust discussion section

Highly-cited papers:

articulate limitations openly,

speculate on mechanistic angles responsibly,

outline future clinical trials.

A strong discussion is disproportionately influential.

🧫 Topics that historically perform well

Cancer immunotherapy mechanisms

Autoimmune biomarkers

Viral infection therapeutics

Neurodegeneration biomarkers

Drug delivery nanoparticles

Microbiome–immune interactions

Resistance/susceptibility pathways

🔍 Article Types with higher acceptance odds

Patterns:

Mechanistic reviews with strong illustration

Systematic reviews + meta-analysis

Translational biomarker studies

Target-based drug repurposing screens

Narrative reviews without figures/tables underperform.

📉 Common reviewer criticisms

Repeated patterns:

✘ Weak novelty (“already known”)
✘ Unclear clinical relevance
✘ No mechanistic rationale for observations
✘ “Fishing expedition” omics
✘ Unsupported claims in abstract
✘ Missing validation cohort

👤 Author profile predictors

Higher success probability if:

previous peer-reviewed translational publications,

funding from national agencies,

participation in clinical collaborations,

preprint engagement demonstrating visibility.

🧵 Ideal manuscript arc

Successful papers follow this logic:

Clinical unmet need

Molecular/immunological mechanism

Diagnostic/therapeutic approach

Validation (cohort or model)

Translational implication

🏁 Summary: strongest predictors

A competitive Biomedicines manuscript typically has:

✅ Explicit translational significance
✅ Disease-focused framing
✅ Mechanistic underpinning of phenotypes
✅ Biomarker or therapeutic relevance
✅ Adequate statistics and power logic
✅ Multi-modal/multi-omics validation
✅ High-quality, annotated figures
✅ Transparent ethics/source documentation

Specialties

Biomedical Engineering

General Medicine

Eligibility Requirements

– Must have received their PhD no more than 10 years prior to 31 December 2024;
– Must have produced ground-breaking research and made a significant contribution to the advancement of biomedicines;
– Candidates must be nominated by senior scientists.

Sponsor Details

Sponsor Institute/Organizations: Biomedicines

Sponsor Type: Corporate/Non-Profit

Address: MDPI Grosspeteranlage 5 4052 Basel Switzerland

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity